These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38087432)

  • 21. Synchronous bilateral clear cell renal cell carcinoma and prostate gland carcinoma on
    Xiao L; Zhang WJ; Ou XH; Li L
    Hell J Nucl Med; 2020; 23(1):88-89. PubMed ID: 32222736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
    Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
    Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.
    Park S; Lee HY; Lee S
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-[
    Zhao Y; Wu C; Li W; Chen X; Li Z; Liao X; Cui Y; Zhao G; Liu M; Fu Z
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):570-579. PubMed ID: 32814979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron Emission Tomography/Computed Tomography with
    Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
    Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative
    Wu C; Cui Y; Zhao Y; Chen X; Liao X; Di L; Yin L; Liu M; Wang R
    Eur J Radiol; 2020 Oct; 131():109218. PubMed ID: 32882538
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Nikpanah M; Paschall AK; Ahlman MA; Civelek AC; Farhadi F; Mirmomen SM; Li X; Saboury B; Ball MW; Merino MJ; Srinivasan R; Jones EC; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2021 Jul; 46(7):3301-3308. PubMed ID: 33688985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
    Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
    Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intense Choline Activity in Renal Cell Carcinoma Without Obvious 18F-FDG Uptake.
    Xia X; Hu F; Qin C; Liu F; Lan X
    Clin Nucl Med; 2019 Jan; 44(1):38-39. PubMed ID: 30371589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Zhang L; Zhao H; Jiang H; Zhao H; Han W; Wang M; Fu P
    Abdom Radiol (NY); 2021 Dec; 46(12):5618-5628. PubMed ID: 34455450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of 18F-FDG PET/CT for detection of recurrence and metastases in renal cell carcinoma-are we underusing PET/CT?
    Pereira M; Punatar CB; Singh N; Sagade SN
    Diagn Interv Radiol; 2022 Sep; 28(5):498-502. PubMed ID: 36218153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
    Guo C; Liu Y; Yang H; Xia Y; Li X; Chen L; Feng Y; Zhang Y; Chen Y; Huang Z
    Br J Radiol; 2024 Mar; 97(1156):859-867. PubMed ID: 38290775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.